Biotech Most Volatile: Celldex Therapeutics (NASDAQ:CLDX), Dyax Corp. (NASDAQ:DYAX), Insmed Incorporated (NASDAQ:INSM), Novavax (NASDAQ:NVAX)



Celldex Therapeutics Inc. (NASDAQ:CLDX) options contracts experienced a new 90-day record for call contracts where a total of 5,803 call contracts were traded in the busy trading session. The contract spread yielded a 0.58 put/call ratio where 1.7 call contracts were traded for each put contract. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock performance was 0.07% in last session and finished the day at $13.73. Traded volume was 4.19million shares in the last session and the average volume of the stock remained 2.40million shares. The beta of the stock remained 2.41. Celldex Therapeutics, Inc. (NASDAQ:CLDX) insider ownership is 0.10%.

Shares of Dyax Corp. (NASDAQ:DYAX) saw a large increase in short interest in January. As of March 31st, there was short interest totaling 4,701,750 shares, an increase of 71.4% from the March 14th total of 2,742,925 shares. Dyax Corp. (NASDAQ:DYAX) dropped -2.78 percent to $6.64 Tuesday on volume of 3.37million shares. The intra-day range of the stock was $6.15 to $6.94. Dyax Corp. (NASDAQ:DYAX) has a market capitalization of $901.32million.

Insmed Incorporated (NASDAQ:INSM) will present at the 13th Annual Needham & Co. Healthcare Conference at the Westin Grand Central Hotel in New York City. Insmed Incorporated (NASDAQ:INSM)’s stock on Apr 15, 2014 reported a decrease of -7.30% to the closing price of $12.57. Its fifty two weeks range is $7.08 -$22.29. The total market capitalization recorded $493.55million. The overall volume in the last trading session was 2.07million shares. In its share capital, INSM has 39.27million outstanding shares.

Novavax, Inc. (NASDAQ:NVAX) is a $805 million biotech that develops vaccines for a number of diseases. The stock is currently in a pullback, but this is not surprising because it is happening everywhere in the healthcare sector. But even so, the pullback in Novavax, Inc. (NASDAQ:NVAX) only creates a buying opportunity for long-term outlook investors. On Tuesday, shares of Novavax, Inc. (NASDAQ:NVAX) dropped -0.81% to close the day at $3.69. Company return on investment (ROI) is -36.40% and its monthly performance is recorded as -29.85%. Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -39.71%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone